Top View
- Table of Contents
- Stembook 2018.Pdf
- CDER List of Licensed Biological Products With
- (INN) for Biological and Biotechnological Substances
- T Cell-Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis
- And Multi-Clonal Antibodies As Higher Quality Substitutes for Animal Sera in Diagnostics 15.10.2020 | Antibody Webinar Series - PETA International Science Consortium
- Medical Policy Update Bulletin
- Array's Three Value Drivers Align with Pfizer's Three Oncology Pillars In
- Multiple Sclerosis and COVID-19 Jan Maresa, Hans-Peter Hartungb
- CHMP Agenda of the 20-23 July 2020 Meeting
- November 2018
- C9050 Injection, Emapalumab-Lzsg, 1 Mg C9122
- Liver Involvement
- Proceedings from the 2Nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome Symposium Held on October 3-4, 2019 Scott W
- Policy Drug(S) Brief Description of Policy Change UM ONC 1038 Emend (Aprepitant Oral Or Add Exclusion Criteria: 1
- A Systematic Review of Anakinra, Tocilizumab, Sarilumab and Siltuximab for Coronavirus-Related Infections
- Severe Pediatric COVID-19 Presenting with Respiratory Failure and Severe Thrombocytopenia Pratik A
- (CHMP) Agenda for the Meeting on 09-12 November 2020 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
- The Clinical Insight
- This Is the Headline
- SOCIETÀ ITALIANA DI FARMACOLOGIA Riconosciuta Con D.M
- New Drug Update 2019
- Pub 100-04 Medicare Claims Processing Centers for Medicare & Medicaid Services (CMS) Transmittal 4396 Date: September 17, 2019 Change Request 11422
- 2018 NEW DRUG THERAPY APPROVALS Impact | Innovation | Predictability | Access
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- Allwell from Buckeye Health Plan Prior Authorization Updates
- 2020 Medicare Prior Authorization Code Listing (PDF)
- Crizanlizumab-Tmca
- Swiss Biotech Report 2018
- Codes Drug Name J3262 Actemra
- Step Therapy Part B Drugs
- The Rheumatology Drugs for COVID-19 Management: Which and When?
- Antibody-Based Immunotherapeutic Strategies for COVID-19
- (CHMP) Agenda for the Meeting on 12-15 October 2020
- Gamifant™ (Emapalumab-Lzsg) (Intravenous) Document Number: IC-0421 Last Review Date: 01/05/2021 Date of Origin: 01/03/2019 Dates Reviewed: 01/2019, 01/2020, 01/2021
- Specialty Drugs Requiring Precertification
- Assessment of Evidence for COVID-19-Related Treatments
- 2021 Medicaid Preapproval Criteria
- Nivolumab Treatment of Relapsed/Refractory Epstein-Barr Virus–Associated Hemophagocytic Lymphohistiocytosis
- (Rituximab) and Truxima (Rituximab-Abbs)- Updated Policy
- Publication Agenda CHMP 07-10 December 2020
- Committee for Medicinal Products for Human Use (CHMP) Agenda for the Meeting on 23-26 March 2020 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
- FORMULARY CHANGES EFFECTIVE 03/01/2021 Medication Name Change Description BAVENCIO 200 MG/10 ML VIAL - Added to Tier 5 Avelumab - PA Added: BAVENCIO (S)
- Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria
- Gamifant, INN-Emapalumab
- Pharmacy Medical Necessity Guidelines: Anti-Emetic Medications
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- Antibodies to Watch in 2018